Form 8-K PACIFIC BIOSCIENCES OF For: May 14

May 17, 2022 4:02 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
0001299130 false 0001299130 2022-05-14 2022-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

May 14, 2022

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34899   16-1590339
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

1305 O’Brien Drive

Menlo Park, California 94025

(Address of principal executive offices) (Zip Code)

 

(650) 521-8000

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   PACB   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02.    departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers

 

On May 14, 2022, Peter Fromen, the Chief Commercial Officer of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his intention to resign, effective as of May 20, 2022, to pursue new opportunities. Mr. Fromen’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

The Company is conducting a search for its next Chief Commercial Officer. Until a successor is appointed, Christian Henry, Chief Executive Officer and President, will take over the Company’s marketing responsibilities, and Chris Seipert, Vice President, Customer Experience, and formerly the Company’s Vice President & General Manager – The Americas & EMEA, will take over the Company’s sales, service and support responsibilities.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pacific Biosciences of California, Inc.
     
  By: /s/ Brett Atkins
    Brett Atkins
    General Counsel
Date: May 17, 2022    

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings